CURE’s lymphoma cancer page is a go-to resource for oncology news and updates in the world of lymphoma cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in lymphoma cancer.
November 18th 2024
As a four-time cancer survivor, I can tell you that survivorship means many things to each survivor.
September 23rd 2024
FDA Approves Keytruda for Relapsed/Refractory PMBCL
June 13th 2018The FDA has granted an accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or those who have relapsed after 2 or more prior lines of therapy.
Survey Sheds Light on Why Some Use Cannabis After Stem Cell Transplant
June 13th 2018Nearly 20 percent of hematopoietic stem cell transplant (HSCT) survivors reported using cannabis, not just to ease physical and emotional side effects, but in the hopes that it would help treat their cancer, according to patient survey results presented at the 2018 of American Society of Clinical Oncology (ASCO) Annual Meeting.
Venclexta Combination Receives Full FDA Approval for CLL, With or Without 17p deletion
June 8th 2018The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.
FDA Approves CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma
May 2nd 2018The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).
Duvelisib Granted Priority Review for CLL and Follicular Lymphoma
April 9th 2018The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.